25
三月 2015

Hua-Zhi and LGC cooperate to increase global rice production

华智与艾吉析合作促进全球水稻丰产增收
Hua-zhi and LGC have today announced a strategic cooperation agreement, for the application of LGC’s innovative KASP™ technology and SNPLine™ genotyping platform in developing a world-leading rice molecular breeding platform.
 华智水稻生物技术有限公司与LGC集团今日宣布达成战略合作协议,华智将以应用LGC公司的KASP创新技术和SNPLine设备建立世界领先的水稻分子育种平台。
 
The aim of this agreement is to improve the effectiveness of rice breeding programs in order to increase rice production and food security throughout the world.
这项协议旨在大幅度提高水稻育种的效率,从而为提高世界水稻的产量和粮食安全带来新的动力和希望。
 
Hua-Zhi uses the application of biotechnology, including molecular breeding tools, in both hybrid rice breeding and in the field of conventional breeding techniques. LGC’s KASP technology has been used to develop over 250,000 validated assays.
艾吉析公司的KASP技术已经被用于25万个位点的开发和验证。 华智将会利用生物技术, 包括分子育种技术,使KASP技术在杂交水稻和常规水稻育种中常规化与实用化。
 
Jian Zhang, General Manager of Hua-zhi Rice Bio-tech Co. Ltd., said, “Choosing LGC’s SNP technology is just a starting point for the collaboration. Our aim is to set up the most advanced rice molecular breeding platform in the world, which will bring the effective rice breeding program up to a much higher level for the rice production and food security in the world. Hua-zhi aims to modernise China’s traditional seed industry through molecular breeding and other cutting-edge technology and this collaboration with LGC is a fundamental step in our achieving this goal. With a highly talented team and a close cooperation with LGC, Hua-zhi is well positioned to develop into a strong leader in global rice research and development.”
华智公司的张健总经理表示,选择艾吉析公司的技术只是双方合作的开始。我们的目标是建立世界上最先进的水稻分子育种平台,为了水稻的增产和世界粮食安全,我们需要利用分子育种技术来大幅度提高水稻育种的效率,相信华智的分子育种研发项目将把水稻育种水平推上一个新台阶。华智专注于利用分子育种和尖端的生物技术为中国种业现代化而努力,与艾吉析的合作是华智实现这个目标极为关键的一步。拥有创业创新技术高端人才以及和艾吉析的紧密合作,华智为成为一个世界水稻研发的领跑者,已打下牢固的基础。
 
Giulio Cerroni, Managing Director, Genomics, LGC, said, “We are very excited that Hua-zhi have chosen to utilise KASP marker assays and deploy our SNPLine automation platform to accelerate their rice breeding program to improve food security in China. With experience in developing over 250,000 validated KASP marker assays LGC is uniquely placed to support Hua-zhi’s ambitions. The results of this cooperation with Hua-zhi will illustrate how LGC’s proprietary genomic technologies and capabilities enable our vision of ‘Science for a safer world’.”
艾吉析基因组学的常务董事Giulio Cerroni 说,我们非常高兴地看到华智选择利用KASP 分子标记 和我们的SNPLine 自动化平台去加速水稻的育种计划,改善中国的食品安全。LGC拥有开发超过25万验证KASP分子标志分析的经验,能够站在独特的位置去支持华智的宏伟目标。与华智这次合作的结果将会使我们看到LGC基因组学的专利技术和平台通量给我们带来的愿景,科技创造更安全的世界。
 
Wei Wu, Business Manager, LGC, China, said, “We are in a business enabling and supporting our customers to achieve their missions through our innovative technologies. China is a fast developing market with incredible potential for LGC’s high throughput, low cost SNP Genotyping technologies, which are used throughout the world to increase diversity and improve crop security. The strategic cooperation with Hua-zhi has once again proven the attractiveness of LGC technologies. I am personally very excited to work with Hua-zhi’s high quality team in the frontier field of rice research.”
艾吉析中国商务经理吴薇说,“我们在业务上通过支持我们的客户有效利用我们的创新技术去实现他们的使命。中国是一个快速发展的市场具有令人难以置信的潜力, LGC的高通量,低成本的SNP基因分型技术,在世界各地被用于农作物的检测以提高农作物的多样性和安全性。与华智的战略合作再次证明LGC技术的吸引力。我个人非常高兴能与华智这样的高水平团队在水稻研究的前沿领域工作。
 
Huazhi focuses on the innovation and advancement of rice biotechnology, including the application, integration and development of molecular breeding technologies. Hua-Zhi works with industry to promote development and promote industrialisation in maintaining food and ecosystem security in China.
华智专注于水稻生物技术的创新和研发,包括分子育种技术的应用,集成和开发。华智与种业公司一起去促进发展中国种业的产业化,以确保粮食与生态安全。
 
LGC scientists have contributed significantly to the development of new genotyping technologies, making affordable projects accessible to a broad range of customers. To date, they have extracted DNA from over 10 million samples, as well as processed over 1 billion PCR reactions.
LGC的科学家为发展新的基因分型技术作出了显著的贡献,使广大科研工作者者可以承担得起他们的基因分型研发项目。到目前为止,他们已经提取了超过1000万份DNA样本,以及解析了超过十亿个PCR反应。